78 results about "Tumour suppressor gene" patented technology

PROBLEMThere are provided induced malignant stem cells capable of in vitro proliferation that are useful in cancer research and drug discovery for cancer therapy, as well as processes for production thereof, cancer cells derived from these cells, and applications of these cells.MEANS FOR SOLVINGAn induced malignant stem cell capable of in vitro proliferation are characterized by satisfying the following two requirements:(1) having at least one aberration selected from among (a) an aberration of methylation (high or low degree of methylation) in a tumor suppressor gene or a cancer-related genetic region in endogenous genomic DNA, (b) a somatic mutation of a tumor suppressor gene or a somatic mutation of an endogenous cancer-related gene in endogenous genomic DNA, (c) abnormal expression (increased or reduced / lost expression) of an endogenous oncogene or an endogenous tumor suppressor gene, (d) abnormal expression (increased or reduced / lost expression) of a noncoding RNA such as an endogenous cancer-related microRNA, (e) abnormal expression of an endogenous cancer-related protein, (f) an aberration of endogenous cancer-related metabolism (hypermetabolism or hypometabolism), (g) an aberration of endogenous cancer-related sugar chain, (h) an aberration of copy number variations in endogenous genomic DNA, and (i) instability of microsatellites in endogenous genomic DNA in an induced malignant stem cell; and(2) expressing genes including POU5F1 gene, NANOG gene, SOX2 gene, and ZFP42 gene.

The invention provides a novel human tumor inhibiting gene and an encoded protein thereof. The gene and the encoded protein can inhibit the growth of tumor cells, are down-regulated in various tumor tissues, and have a close relation with the generation of tumors. The gene and the encoded protein and derivatives thereof can be used for the diagnosis, treatment and drug screening of various tumors.

Embodiments of the invention include methods and compositions including viral composition that have high transduction efficiencies in vivo, in vitro and ex vivo. The viral composition include a viral vector and a protamine molecule, wherein the viral vector includes a polynucleotide encoding a tumor suppressor gene. The methods of the invention include administering the viral composition to a patient or subject for treatment of disease, in particular cancer, that is characterized by a reduced vector-induced production of neutralizing antibodies and a decreased vector-induced toxicity as compared to delivery of viral vectors alone.

Disclosed is a cancer vaccine composition for a human leukocyte antigen (HLA)-A*0206-positive subject, which is characterized by comprising a protein which is a gene product of a tumor suppressor gene WT1 or a partial peptide of the protein.

This invention provides a genetically tractable in situ non-human animal model for hepatocellular carcinoma. The model is useful, inter alia, in understanding the molecular mechanisms of liver cancer, in understanding the genetic alterations that lead to chemoresistance or poor prognosis, and in identifying and evaluating new therapies against hepatocellular carcinomas. The liver cancer model of this invention is made by altering hepatocytes to increase oncogene expression, to reduce tumor suppressor gene expression or both and by transplanting the resulting hepatocytes into a recipient non-human animal.

The present invention is directed to methods of using HSS1 (Hematopoietic Signal peptide-containing Secreted 1), HSM1 (Hematopoietic Signal peptide-containing Membrane domain-containing 1), or a combination thereof in the treatment of various cancers, such as brain cancers.